2.15
Precedente Chiudi:
$2.28
Aprire:
$2.26
Volume 24 ore:
1.28M
Relative Volume:
0.74
Capitalizzazione di mercato:
$128.79M
Reddito:
-
Utile/perdita netta:
$-44.80M
Rapporto P/E:
-2.8667
EPS:
-0.75
Flusso di cassa netto:
$-30.67M
1 W Prestazione:
-3.15%
1M Prestazione:
-20.07%
6M Prestazione:
-56.12%
1 anno Prestazione:
-42.36%
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Nome
Aldeyra Therapeutics Inc
Settore
Industria
Telefono
781-761-4904
Indirizzo
131 HARTWELL AVENUE, LEXINGTON, MA
Confronta ALDX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ALDX
Aldeyra Therapeutics Inc
|
2.15 | 132.97M | 0 | -44.80M | -30.67M | -0.75 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-04-03 | Aggiornamento | Oppenheimer | Perform → Outperform |
2024-04-02 | Ripresa | H.C. Wainwright | Buy |
2022-04-27 | Ripresa | H.C. Wainwright | Buy |
2021-02-08 | Iniziato | H.C. Wainwright | Buy |
2020-12-16 | Iniziato | Berenberg | Buy |
2020-10-30 | Iniziato | Jefferies | Buy |
2020-10-16 | Iniziato | BTIG Research | Buy |
2020-09-22 | Iniziato | Alliance Global Partners | Buy |
2020-05-12 | Iniziato | Oppenheimer | Outperform |
2018-12-04 | Iniziato | Citigroup | Buy |
2018-09-26 | Reiterato | Cantor Fitzgerald | Overweight |
2018-09-13 | Iniziato | Janney | Buy |
2018-01-26 | Iniziato | Seaport Global Securities | Buy |
2016-09-26 | Iniziato | H.C. Wainwright | Buy |
2016-07-01 | Iniziato | Stifel | Buy |
2015-07-01 | Iniziato | Canaccord Genuity | Buy |
2015-03-25 | Iniziato | Chardan Capital Markets | Buy |
2015-03-20 | Reiterato | H.C. Wainwright | Buy |
2014-11-18 | Iniziato | H.C. Wainwright | Buy |
2014-06-19 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie
Trading (ALDX) With Integrated Risk Controls - news.stocktradersdaily.com
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference | ALDX Stock News - GuruFocus
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference - Business Wire
Northern Trust Corp Purchases 16,894 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Acquired by Deutsche Bank AG - Defense World
D. E. Shaw & Co. Inc. Sells 146,198 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Q3 Earnings Forecast for ALDX Issued By Leerink Partnrs - Defense World
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): When Will It Breakeven? - Yahoo Finance
HC Wainwright Has Strong Forecast for ALDX FY2029 Earnings - Defense World
Q2 EPS Estimate for Aldeyra Therapeutics Lifted by Analyst - Defense World
Aldeyra Therapeutics (NASDAQ:ALDX) Raised to “Sell” at StockNews.com - Defense World
Balyasny Asset Management L.P. Acquires New Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics (NASDAQ:ALDX) Given “Buy” Rating at HC Wainwright - Defense World
ALDX: HC Wainwright & Co. Reiterates Buy Rating with $10 Target | ALDX Stock News - GuruFocus
(ALDX) Trading Report - news.stocktradersdaily.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - FinancialContent
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock Holdings Lessened by Price T Rowe Associates Inc. MD - Defense World
Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical ... - Eagle-Tribune
Bragar Eagel & Squire, P.C. Is Investigating Organon, - GlobeNewswire
Aldeyra Therapeutics, Inc. SEC 10-Q Report - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra - Bluefield Daily Telegraph
Hsbc Holdings PLC Acquires Shares of 10,457 Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - PR Newswire
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Barclays PLC Has $376,000 Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, - GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical ... - Eagle-Tribune
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm - TradingView
Aldeyra Therapeutics Drops To US$2.10, Yet Insiders May Have Sold Too Early - simplywall.st
ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with - GlobeNewswire
Aldeyra makes third run at FDA approval for dry eye drug - The Pharma Letter
Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data - insights.citeline.com
Aldeyra DED phase III hits but reproxalap field goal fumbled - BioWorld MedTech
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After - GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc.(ALDX) Investors of a Class Action Lawsuit and Upcoming Deadline - Barchart.com
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Aldeyra plots third FDA filing for dry eye disease drug after latest Phase 3 data - Endpoints News
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Ey - GuruFocus
Aldeyra (ALDX) Hits Primary Endpoint in Dry Eye Treatment Trial - GuruFocus
Aldeyra (ALDX) Hits Primary Endpoint in Dry Eye Treatment Trial | ALDX Stock News - GuruFocus
Breakthrough in Dry Eye Treatment: Aldeyra's Reproxalap Achieves Significant Phase 3 Results, FDA Filing Next - Stock Titan
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap - Business Wire
ALDX SECURITIES ALERT: Lose Money on Aldeyra Therapeutics, - GlobeNewswire
Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com
Invesco Ltd. Cuts Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) - GlobeNewswire
ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law - GlobeNewswire Inc.
Press Release Distribution & PR Platform - ACCESS Newswire
Renaissance Technologies LLC Purchases 59,700 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Ongoing Securities Investigation - TradingView
Aldeyra Therapeutics Inc (ALDX) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Aldeyra Therapeutics Inc Azioni (ALDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):